2016_Head & Neck COURSE BOOK

RTOG 1016 de‐escalation study p16+ oropharyngeal carcinomas T1‐2,N2a‐3 or T3‐4 any N

RT 70Gy/35f/6 wks + cisplatin 100mg/m² x 2

Stratify: T 1‐2

T3‐4 N0‐2a N2b‐c

ZE

Closed 2013 after 987 patients accrued

>10 PY> Zubrod 1‐2

ANDOMI

R

RT 70Gy/35f/6 wks + cetuximab for 8 weeks